Loading
A phase 2 trial of Izalontamab brengitecan, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT06475300 by Sichuan Baili Pharmaceutical Co., Ltd., with 570 participants planned, started 2024-06-25 and due to reach its primary completion in 2027-06. Interventions recorded: BL-B01D1, PD-1 Monoclonal Antibody, Pemetrexed Disodium. Conditions listed: Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor. No results are recorded here; the registry entry is the source.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Nasopharyngeal carcinoma.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Pemetrexed, Small-cell lung cancer.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Nasopharyngeal carcinoma.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Pemetrexed, Small-cell lung cancer.